Skip to main content
NeuroWiki
Acute

DESTINY II Trial: Hemicraniectomy in Older Patients With Malignant MCA Stroke

In patients aged 61 or older with malignant MCA infarction, does early decompressive hemicraniectomy within 48 hours improve survival and functional outcome compared with conservative intensive care?

Juttler et al. (NEJM 2014) · doi:10.1056/NEJMoa1311367 · 112 patients

Population

Included

  • Age 61 years or older
  • Malignant MCA infarction with clinical and imaging criteria for expected fatal brain swelling
  • Surgery within 48 hours of stroke onset
  • Pre-stroke mRS 0-1

Excluded

  • Age younger than 61 years
  • Pre-existing disability (mRS 2 or higher)
  • Posterior circulation or bilateral infarcts
  • Hemorrhagic transformation before randomization
  • Major comorbidities limiting life expectancy

Source: Juttler et al., N Engl J Med 2014· Retrieved 2026-06-09

Primary Outcome — Survival Without Severe Disability (mRS 0-4) at 6 Months

112 patients aged 61-82; early hemicraniectomy vs conservative intensive care

Primary endpoint met — but no patient achieved good functional outcome

0% of patients in either group achieved mRS 0-2 (independent function). Virtually all surgical survivors who met the primary endpoint had mRS 4 (severe disability, dependent for most bodily needs). Surgery reduces the chance of dying from 70% to 33% — it does not restore function.

HemicraniectomyBetter outcome
38 / 100
Conservative Treatment
18 / 100

Survival Without Being Bedbound or Dead (mRS 0-4) at 6 Months

Risk ratio OR 2.9195% CI 1.06–7.49p = 0.04

Study Arms

Agent
Decompressive hemicraniectomy
Route
Surgical
Duration
Initiated within 48 hours after onset of symptoms and not later than 6 hours after randomization
Co-interventions
Conducted in the ICU with the same conservative protocol available to both groups: basic ICU therapy for stroke; osmotherapy with mannitol, glycerol, or hypertonic hydroxyethyl starch; sedation; intubation and mechanical ventilation; hyperventilation; and buffer solutions.

Large hemicraniectomy with a bone-flap diameter of at least 12 cm, combined with duraplasty. Performed in addition to ICU conservative care.

Trial Design

Type

  • Randomized controlled trial in older adults
  • Hemicraniectomy vs conservative intensive care treatment
  • Malignant MCA infarction with treatment within 48 hours
  • Primary endpoint: survival without severe disability (mRS 0-4) at 6 months

Timeline

Germany; patients aged 61-82 years

N

112

Enrollment

112 patients aged 61-82 at multiple German centers (planned 188; stopped early for enrollment difficulty). Open-label randomized trial with blinded outcome assessment. Surgery within 48 hours of stroke onset. Published NEJM 2014.

Bedside Pearl

DESTINY II is a positive trial for survival and surgery is a legitimate option, but it must be offered with the right framing. Tell the family: 'Surgery reduces the chance of dying from 70% to 33%. But 0% of patients who had surgery regained the ability to care for themselves. Nearly all surgical survivors needed help for most bodily needs (mRS 4).' Do not show this trial to a family as evidence that their loved one will do well. Show it as evidence that surgery shifts the outcome from death to severe disability. The family and patient (if able) must decide whether that shift is consistent with their values.

Trial lineage

Hemicraniectomy for malignant MCA infarction

Three near-simultaneous European RCTs (DECIMAL, DESTINY, HAMLET) established that decompressive hemicraniectomy reduces mortality in younger patients with space-occupying MCA infarction. The pooled analysis underpins the AHA/ASA Class I recommendation in patients up to 60 years. DESTINY II later extended the question to patients over 60, where survival is preserved but most survivors have moderate-to-severe disability.

  1. 2007
  2. 2007
  3. 2009
  4. 2014
    DESTINY II Trial· this pagePOSITIVE

NeuroWiki is a clinical reference. It does not substitute for your clinical judgment, current guidelines, or your institution's protocol. Verify before acting. Do not enter patient names, MRNs, or dates of birth. Privacy Policy